Compare STIM & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STIM | SDHC |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.6M | 102.3M |
| IPO Year | 2018 | 2023 |
| Metric | STIM | SDHC |
|---|---|---|
| Price | $2.02 | $13.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $14.60 |
| AVG Volume (30 Days) | ★ 1.8M | 87.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | $52,776,000.00 | ★ $971,116,000.00 |
| Revenue This Year | $11.10 | $4.21 |
| Revenue Next Year | $11.92 | $11.07 |
| P/E Ratio | ★ N/A | $11.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $11.13 |
| 52 Week High | $4.84 | $23.50 |
| Indicator | STIM | SDHC |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 49.55 |
| Support Level | $1.23 | $13.36 |
| Resistance Level | $2.13 | $14.49 |
| Average True Range (ATR) | 0.14 | 0.85 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 84.90 | 38.81 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.